Opinion on Pharmaceuticals and Healthcare in United Kingdom

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
CommentWire
CommentWire

Wyeth: UK offers Efexor relief

Having concluded a new review of the latest safety evidence related to Wyeth's serotonin and noradrenergic reuptake inhibitor Efexor, UK regulators have eased the barriers restricting use of the drug. The updated prescribing advice should help Wyeth stabilize sales of Efexor while also enabling the company to plan more effectively for the launch of its follow-on compound, desvenlafaxine.

Published By Datamonitor
02 Jun 2006
CommentWire
CommentWire

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003
CommentWire
CommentWire

Women's mental health: no easy thinking, no easy solutions

Published By Datamonitor
21 Sep 2001
CommentWire
CommentWire

Women's health: more HPV risk than expected

In the new survey, featuring women in their first relationship, 74% of respondents reportedly used barrier contraception. Yet nearly half developed some form of HPV infection. Companies such as Merck and Origenix, with vaccines in development for the virus, are likely to see significant revenues when their products hit the market.

Published By Datamonitor
15 Feb 2002
ResearchWire
ResearchWire

Women's health: 7.2 million PCOS sufferers in the US

Published By Datamonitor
08 May 2002
ResearchWire
ResearchWire

Women's health: 20 million HPV sufferers in the US

Published By Datamonitor
15 May 2002
Expert View
Expert View

Will clinical trials go mobile

Published By Datamonitor
20 Jul 2001
ResearchWire
ResearchWire

Vinka alkaloids: market to fall 17% by 2007

Published By Datamonitor
16 May 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.